| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EDSA | Series A-1 Convertible Preferred Shares | Award | +150 | 150 | Oct 30, 2024 | Common Stock | 435K | $3.45 | Held by Pardeep Nijhawan Medicine Professional Corporation | F1, F2, F3, F4 | |||
| transaction | EDSA | Warrants (right to buy) | Award | +327K | 327K | Oct 30, 2024 | Common Stock | 327K | $3.45 | Held by Pardeep Nijhawan Medicine Professional Corporation | F3, F4 |
| Id | Content |
|---|---|
| F1 | The Preferred Shares are perpetual and therefore have no expiration date. |
| F2 | Each Preferred Share is convertible at any time, at the option of the holder, into a number of common shares determined by dividing the stated value of the Preferred Share ($10,000 per share), plus any accrued and unpaid dividends, by the conversion price at the time of conversion. Until the three-year anniversary of the day of issuance, holders of Preferred Shares are entitled to an annual return equal to 10% of the stated value per Preferred Share payable by the issuance of common shares at the conversion price upon a buy-back by the Issuer, liquidation or on conversion at the conversion price (calculated daily). |
| F3 | On October 30, 2024, the Reporting Person purchased in a private placement, (i) 150 shares of the Issuer's newly designated Series A-1 Convertible Preferred Shares (the "Preferred Shares"), stated value $10,000 per share and (ii) warrants (the "Warrants") to purchase up to an aggregate of 326,560 common shares. The Preferred Shares are immediately convertible, and the Warrants are immediately exercisable, at $3.445 per share, in each case, to the extent that after giving effect to such conversion and/or exercise the Reporting Person and his affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding common shares of the Issuer. The Preferred Shares and the Warrants are being sold together in a fixed combination of one Preferred Share and a Warrant to purchase a number of common shares equal to 75% of the common shares underlying the Preferred Share at a combined purchase price of $10,272.13. |
| F4 | Pardeep Medicine Professional Corporation is wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |